bb-21217

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug Namebb-21217
Drug Alias NameAnti-BCMA CAR T-cell- bluebird biobb-21217
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active Companies2seventy Bio Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A